LEXX
Lexaria Bioscience Corp.
There isn't enough reported data to score LEXX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LEXX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
LEXX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LEXX PE Valuation
LEXX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LEXX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect LEXX's losses to grow, with revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LEXX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.25 | +$5.46 |
| Q1 2026 | -$7.20 | +$2.05 |
| Q4 2025 | -$8.55 | -$0.80 |
| Q3 2025 | -$9.90 | -$2.85 |
| Q2 2025 | -$10.71 | -$4.77 |
| Q1 2025 | -$9.25 | -$0.60 |
| Q4 2024 | -$7.75 | +$3.39 |
| Q3 2024 | -$7.05 | +$6.83 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 149% for LEXX versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
LEXX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $20K | -89% |
| Q3 2025 | $174K | +107% |
| Q2 2025 | $174K | +107% |
| Q1 2025 | $174K | +20% |
| Q4 2024 | $183.9K | +22% |
| Q2 2024 | $84K | -9.8% |
| Q1 2024 | $145K | +314% |
| Q4 2023 | $151.3K | +49% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for LEXX versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -7260% | -5679 points |
| Q3 2025 | -1545% | +1078 points |
| Q2 2025 | -2155% | -81 points |
| Q1 2025 | -1581% | -1120 points |
| Q4 2024 | -1463% | -710 points |
| Q3 2024 | -2623% | N/A |
| Q2 2024 | -2075% | N/A |
| Q1 2024 | -461% | N/A |
LEXX's operating margin was −7260% last quarter, down 5797 points from the same quarter a year ago, near the bottom of its range since 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
LEXX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.6M | +$1.9M |
| Q1 2026 | -$2.2M | -$706.8K |
| Q4 2025 | -$984.1K | +$1.8M |
| Q3 2025 | -$2.6M | -$707.8K |
| Q2 2025 | -$3.6M | -$2.3M |
| Q1 2025 | -$1.5M | -$878.3K |
| Q4 2024 | -$2.8M | -$1.6M |
| Q3 2024 | -$1.9M | -$244.6K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with LEXX at down 26%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
LEXX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +24.1K shares |
| 1 year | +36% | +434K shares |
| 3 years | +314% | +1.3M shares |
| 5 years | +726% | +1.5M shares |
| Available history | +857% | +1.5M shares |
LEXX has 2M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LEXX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LEXX Net Leverage
LEXX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LEXX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 13.6 | Oversold |
LEXX's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LEXX PE vs Healthcare Sector
LEXX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LEXX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.45 | 21% above |
| 20 week MA | $6.32 | 34% below |
| 50 week MA | $9.25 | 55% below |
| 100 week MA | $14.0 | 70% below |
| 200 week MA | $23.3 | 82% below |
LEXX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LEXX on trend strength, trading above more of its moving averages.
LEXX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $68.7 | $62.9 | -8.5% |
| 2022 | $62.9 | $36.8 | -42% |
| 2023 | $36.8 | $18.8 | -49% |
| 2024 | $18.8 | $34.4 | +83% |
| 2025 | $34.4 | $7.96 | -77% |
| 2026 YTD | $7.96 | $4.18 | -47% |
LEXX has finished lower in four of the last five years. It's down 47% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LEXX on returns for 2026, with the stronger performance.